Direct and indirect pathways of immunity to pancreatic islet transplants

Transplantation Reviews

Volumn 12, Issue 2, 1998, Pages 85-95

  Gill, Ronald G ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0007791453     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(98)80033-5     Document Type: Article

References (124)

1. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977
2. Sutherland DE, Gruessner RW, Gores PF, et al: Pancreas transplantation: An update. Diabetes Metab Rev 1995, 11: 337
3. Sutherland DE, Gores PF, Hering BJ, et al: Islet transplantation: An update. Diabetes Metab Rev 1996, 12:137
4. Gray DWR: The development and current status of pancreas and islet transplantation. Transpl Immunol 1994, 2:127-129
5. Shizuru JA, Gregory AK, Chao CTB, et al: Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. Science 1987, 237:278
6. + T cell in allograft rejection. J Immunol 1987, 139:4022
7. Kaufman DS, Kong CS, Shizuru JA, et al: Use of anti-L3T4 and anti-Ia treatments for prolongation of xenogeneic islet transplants. Transplantation 1988, 46:210
8. + T-lymphocytes in rejection by mice of fetal pig proislet xenografts. Diabetes 1989, 38:217(suppl 1)
9. Mandel TE, Koulmanda M, Loudovaris T, et al: Islet grafts in NOD mice: A comparison of iso-, allo-, and pig xenografts. Transplant Proc 1989, 21:3813
10. Lacy PE, Ricordi C, Finke EH: Effect of transplantation site and αL3T4 treatment on survival of rat, hamster, and rabbit islet xenografts in mice. Transplantation 1989, 47:761
11. + T-lymphocytes. Transplant Proc 1992, 24:2877
12. Krieger NR, Ito H, Fathman CG: Rat pancreatic islet skin xenograft survival in CD4 and CD8 knockout mice. J Autoimmun 1997, 10:309
13. + T cells. J Exp Med 1987, 166:823
14. + T-cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988, 140:52
15. Shizuru JA, Taylor-Edwards C, Banks BA, et al: Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 1988, 240:659
16. + T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991, 88:527
17. Wang Y, Hao L, Gill RG, et al: Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 1987, 36:535
18. Gill RG: The role of direct and indirect antigen presentation in the response to islet xenografts. Transplant Proc 1992, 24:642
19. Parr EL, Lafferty KJ, Bowen KM, et al: H-2 complex and Ia antigens on cells dissociated from mouse thyroid glands and islets of Langerhans. Transplantation 1980, 30:142
20. Faustman D, Hauptfeld V, Davie JM, et al: Murine pancreatic beta cells express H-2K and H-2D but not Ia antigens. J Exp Med 1980, 151:1563
21. VanBuskirk AM, Wakely ME, Orosz CG: Transfusion of polarized Th2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996, 62:229
22. Gill R, Wolf L, Daniel D, et al: CD4 T cells are both necessary and sufficient for islet xenograft rejection. Transplant Proc 1994, 26:1203
23. Rosenberg AS, Finbloom DS, Maniero TG, et al: Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-γ monoclonal antibody. J Immunol 1990, 144:4648
24. Lafferty KL, Cunningham AJ: A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975, 53:27
25. Talmage D, Woolnough J, Hemmingsen H, et al: Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc Natl Acad Sci USA 1977, 74:1610
26. June CH, Ledbetter JA, Linsley PS, et al: Role of the CD28 receptor in T-cell activation. Immunol Today 1990, 11:211
27. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin 2 production and immunotherapy. Cell 1992, 71:1065
28. + T lymphocytes. J Immunol 1992, 148:1985
29. Swain SL: T cell subsets and the recognition of MHC class. Immunol Rev 1983, 74:129
30. Kurts C, Heath WR, Carbone FR, et al: Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996, 184:923
31. Brossart P, Bevan MJ: Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997, 90:1594
32. Lafferty KJ, Prowse SJ, Simeonovic CJ: Immunobiology of tissue transplantation: A return to the passenger leukocyte concept. Annu Rev Immunol 1983, 1:143
33. Lafferty K, Bootes A, Dart G, et al: Effect of organ culture on the survival of thyroid allografts in mice. Transplantation 1976, 22:138
34. Bowen K, Andrus L, Lafferty K: Successful allotransplantation of mouse pancreatic islets to nonimmunosuppressed recipients. Diabetes 1980, 29:98 (suppl 1)
35. Gill RG, Wolf L: Immunobiology of cellular transplantation. Cell Transplant 1995, 4:361
36. Bowen K, Prowse S, Lafferty K: Reversal of diabetes by islet transplantation: Vulnerability of the established allograft. Science 1981, 213:1261
37. Lacy P, Davie J, Finke E: Prolongation of islet allograft survival following in vitro culture (24°C) and a single injection of ALS. Science 1979, 204:312
38. Faustman D, Hauptfeld V, Lacy P, et al: Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci USA 1981, 78:5156
39. Morrow C, Sutherland D, Steffes M, et al: Lack of donor-specific tolerance in mice with established anti-Ia-treated islet allografts. Transplantation 1983, 36:691
40. Faustman D, Steinman R, Gebel H, et al: Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci USA 1984, 81:3864
41. Lau H, Reemtsma K, Hardy M: Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft. Science 1984, 223:607
42. La Rosa F: Abrogation of mouse pancreatic islet allograft rejection by a four-day culture. Transplantation 1988, 46:330
43. Hegre O, Hickey G, Marshall S, et al: Modification of allograft immunogenicity in perinatal islets isolated and purified in vitro. Transplantation 1984, 37:227
44. Hullett DA, Landry AS, Leonard DK, et al: Enhancement of thyroid allograft survival following organ culture. Transplantation 1989, 47:24
45. La Rosa FG, Talmage DW: Major histocompatibility complex antigen expression on parenchymal cells of thyroid allografts is not by itself sufficient to induce rejection. Transplantation 1990, 49:605
46. Coulombe M, Yang H, Guerder S, et al: Tissue Immunogenicity: The role of MHC antigen and the lymphocyte costimulator B7-1. J Immunol 1996, 157:4790
47. Zheng XX, Sayegh MH, Zheng XG, et al: The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol 1997, 159:1169
48. Golding H, Singer A: Role of accessory cell processing and presentation of shed H-2 alloantigens in allospecific cytotoxic T lymphocyte responses. J Immunol 1984, 133:597
49. Benichou G, Takizawa P, Oslon C, et al: Donor MHC peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992, 175:3038
50. Fangmann J, Dalchau R, Sawyer G, et al: T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur J Immunol 1992, 22:1525
51. Fangmann J, Dalchau R, Fabre J: Rejection of skin allografts by indirect allorecognition of donor class I MHC peptides. J Exp Med 1992, 175:1521
52. Chen W, Murphy B, Waaga AM, et al: Mechanisms of indirect allorecognition in graft rejection. Transplantation 1996, 62:705
53. Stock PG, Ascher NL, Chen S, et al: Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets. Transplantation 1991, 52:704
54. Gill RG: T cell-T cell collaboration in allograft responses. Curr Opin Immunol 1993, 5:782
55. Lee RS, Grusby MJ, Gkimcher LH, et al: Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994, 179:865
56. Agostino M, Prowse SJ, Lafferty KJ: Stabilization of islet allografts by treatment of recipients with ultraviolet irradiated donor spleen cells. Aust J Exp Biol Med Sci 1983, 61:517
57. Wolf LA, Coulombe M, Gill RG: Donor antigen-presenting cell-independent rejection of islet xenografts. Transplantation 1995, 60:1164
58. Markmann JF, Bassiri H, Desai NM, et al: Indefinite survival of MHC class I-deficient murine pancreatic islet allografts. Transplantation 1992, 54:1085
59. Osorio RW, Ascher NL, Stock PG: Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen. Transplantation 1994, 57:783
60. Warnock GI, Tsapogas P, Ryan EA, et al: Natural history of insulin independence after transplantation of multidonor cryopreserved pancreatic islets in type 1 diabetic humans. Transplant Proc 1995, 27:3159
61. Auchincloss HJ: Xenogeneic transplantation: A review. Transplantation 1988, 46:1
62. Piatt JL, Bach FH: The barrier to xenotransplantation. Transplantation 1991, 52:937
63. Galili U: Interaction of the natural anti-Gal antibody with α-galactsyl epitopes: A major obstacle for xenotransplantation in humans. Immunol Today 1993, 14:480
64. Auchincloss HJ: Xenografting: A review. Transplant Rev 1990, 4:14
65. Korsgren O, Jansson L: Discordant cellular xenografts revascularized in intermediate athymic hosts fail to induce a hyperacute rejection when transplanted to immunocompetent rats. Transplantation 1994, 57:1408
66. Korbutt GS, Aspeslet L, Ao Z, et al: Procine islet cell antigens are recognized by xenoreactive natural human antibodies of both IgG and IgM subtypes. Transplant Proc 1996, 28:837
67. Lafferty KJ, Jones MAS: Reactions of the graft-versus-host (GVH) type. Aust J Exp Biol Med Sci 1969, 47:17
68. McCune JM, Namikawa R, Kaneshima H, et al: The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988, 241: 1632
69. Kawamura T, Niguma T, Fechner JHJ, et al: Chronic human skin graft rejection in severe combined immunodeficient mice engrafted with human PBL from an HLA presensitized donor. Transplantation 1992, 53:659
70. Rouleau M, Namikawa R, Antonenko S, et al: Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J Immunol 1996, 157: 5710
71. Korngold R, Sprent J: Surface markers of T cells causing lethal graft-versus-host disease to class I vs class II H-2 differences. J Immunol 1985, 135:3004
72. Sachs DH, Bach FH: Immunology of xenograft rejection. Hum Immunol 1990, 28:245
73. Alter BJ, Bach FH: Cellular basis of the proliferative response of human T cells to mouse xenoantigens. J Exp Med 1990, 171:333
74. Lafferty KJ, Warren HS, Woolnough JA, et al: Immunological induction of T lymphocytes: Role of antigen and the costimulator. Blood Cells 1978, 4:395
75. Moses RD, Winn HJ, Auchincloss HJ: Evidence that multiple defects in cell-surface molecule interactions across species differences are responsible for diminished xenogeneic T-cell responses. Transplantation 1992, 53:203
76. Woolnough J, Misko I, Lafferty KJ: Cytotoxic and proliferative lymphocyte responses to allogeneic and xenogeneic antigens in vitro. Aust J Exp Bio Med Sci 1979, 57:467
77. Collins MKL: Species specificity of interleukin 2 binding to individual receptor components. Eur J Immunol 1989, 19: 1517
78. Kalinke U, Arnold B, Hammerling GJ: Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27. Nature 1990, 348:642
79. Vignali DAA, Moreno J, Schiller D, et al: Species-specific binding of CD4 to the β2 domain of major histocompatibility complex class II molecules. J Exp Med 1992, 175:925
80. Yoshizawa K, Yano A: Mouse T lymphocytes proliferative responses specific for human MHC products in mouse anti-human xenogeneic MLR. J Immunol 1984, 132:2820
81. Lucas PJ, Shearer GM, Neudorf S, et al: The human anti-murine xenogeneic cytotoxic response I: Dependence on responder antigen-presenting cells. J Immunol 1990, 144: 4548
82. + helper T cells and self antigen-presenting cells in the mouse. J Exp Med 1990, 172:567
83. Barzaga-Gilbert E, Grass D, Lawrence S, et al: Species specificity and augmentation of responses to class II major histocompatibility complex molecules in human CD4 transgenic mice. J Exp Med 1992, 175:1707
84. Irwin MJ, Heath WR, Sherman LA: Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989, 170:1091
85. Greenstein JL, Foran JA, Gorga JC, et al: The role of T cell accessory molecules in the generation of class II-specific xenogeneic cytolytic T cells. J Immunol 1986, 136:2358
86. Rollins SA, Kennedy SP, Chodera AJ, et al: Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2. Transplantation 1994, 57:1709
87. Yamada K, Sachs DH, DerSimonian H: Human anti-porcine xenogeneic T cell response: Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol 1995, 155:5249
88. Lucas PJ, Bare CV, Gress RE: The human anti-murine xenogeneic cytotoxic response. II: Activated murine antigen-presenting cells directly stimulate human T helper cells. J Immunol 1995, 154:3761
89. Chabot J, Weber C, Hardy M, et al: Synergy of ALS and UV-B in prolongation of primate-to-mouse islet xenograft survival. Transplant Proc 1987, 19:1160
90. Ricordi C, Lacy PE, Sterbenz K, et al: Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival. Proc Natl Acad Sci USA 1987, 84:8080
91. Zeng Y, Gage A, Montag A, et al: Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-CAM-1 antibodies. Transplantation 1994, 58:681
92. Faustman D, Coe C: Prevention of xenograft rejection by masking of donor HLA class I antigens. Science 1991, 252:1700
93. Carel J, Schreiber RD, Falqui L, et al: Transforming growth factor β decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. Proc Natl Acad Sci USA 1990, 87:1591
94. Serie JR, Hickey GE, Schmitt RV, et al: Prolongation of culture-isolated neonatal islet xenografts without immunosuppression. Transplantation 1983, 36:6
95. + or B lymphocytes, can reject xenogeneic skin grafts. Xenotransplantation 1994, 1:8
96. Benda B, Karlsson-Parra A, Ridderstad A, et al: Xenograft rejection of porcine islet-like cell clusters in immunoglobulin-or Fc-receptor γ-deficient mice. Transplantation 1996, 62: 1207
97. Murphy B, Auchincloss H, Carpenter CB, et al: T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation 1996, 61:1133
98. + T cells in major histocompatibility complex class II-deficient mice. Science 1991, 253:1417
99. Sprent J, Schaefer M: Properties of purified T cells subsets. I: In vitro responses to class I vs. class II H-2 alloantigens. J Exp Med 1985, 162:2068
100. Matzinger P, Bevan MJ: Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977, 29:1
101. Sutherland DER, Sibley R, Xu XZ, et al: Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Transplant Assoc Am Physicians 1984, 97:80
102. Terada M, Lennartz K, Mullen Y: Allogeneic and syngeneic pancreas transplantation in non-obese diabetic mice. Transplant Proc 1987, 19:960
103. Naji A, Silvers W, Kimura H, et al: Influence of islet and bone marrow transplantation on the diabetes and immunodeficiency of BB rats. Metabolism 1983, 32:62 (suppl 1)
104. + islet-specific T-cell clone. Diabetes 1992, 41:1603
105. a donors. Diabetes 1993, 42:44
106. Wegmann DR, Shehadeh N, Lafferty KL, et al: Establishment of islet-specific T-cell lines and clones from islet isografts placed in spontaneously diabetic NOD mice. J Autoimmun 1993, 6:517
107. Daniel D, Gill R, Schloot N, et al: Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T-cell clones isolated from NOD mice. Eur J Immunol 1995, 25:1056
108. Peterson JD, Haskins K: Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones: Differential requirement for CD8 T cells. Diabetes 1996, 45:328
109. Wong FS, Visintin I, Wen L, et al: CD8 T-cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996, 183:67
110. Osorio RW, Ascher NL, Jaenisch R, et al: Major histocompatibility complex class I deficiency prolongs islet allograft survival. Diabetes 1993, 42:1520
111. Wegmann DR, Norbury-Glaser M, Daniel D: Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994, 24:1853
112. Crawford M, Daniel D, Wegmann D, et al: Autoimmune islet damage mediated by insulin-specific T cells. Transplant Proc 1997, 29:758
113. Rosenberg AS, Singer A: Evidence that the effector mechanism of skin allograft rejection is antigen-specific. Proc Natl Acad Sci USA 1988, 85:7739
114. Sutton R, Gray DWR, McShane P, et al: The specificity of rejection and the absence of susceptibility of pancreatic islet β cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J Exp Med 1989, 170:751
115. Pukel C, Baquerizo H, Rabinovitch A: Destruction of rat islet cell monolayers by cytokines: Synergistic interactions of interferon-γ, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes 1988, 37:133
116. Mandrup-Poulsen T, Spinas GA, Prowse SJ, et al: Islet cytotoxicity of interleukin 1: Influence of culture conditions and islet donor characteristics. Diabetes 1987, 36:641
117. Rabinovitch A, Sumoski W, Rajotte RV, et al: Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 1990, 71:152
118. Bendtzen K, Mandrup-Poulsen T, Nerup J, et al: Cytotoxicity of human pI7 interleukin I for pancreatic islets of Langerhans. Science 1986, 1545
119. Nomikos IN, Prowse SJ, Carotenuto P, et al: Combined treatment with nicotinamide and desferoxamine prevents islet allograft destruction in NOD mice. Diabetes 1986, 35:1302
120. 2 radicals in 'autoimmune' diabetes. Immunol Cell Biol 1989, 67:85
121. Ahmed KR, Guo TB, Gaal KK: Islet rejection in perforin-deficient mice: The role of perforin and Fas. Transplantation 1997, 63:951
122. Diamond A, Yang H, Bolwerk A, et al: Mechanism of CD8-dependent rejection of pancreatic islet allografts. Presented at the 16th Annual Meeting of the American Society of Transplant Physicians (abstr). 1997
123. Hao L, Wang Y, Gill RG, et al: Role of lymphokine in islet allograft rejection. Transplantation 1990, 49:609
124. - epidermal cells. J Immunol 1989, 143:2452